-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$43.8840.42% Upside
Recent Analyst Forecasts and Stock Ratings
Dyne Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Dyne Therapeutics, Inc.?
Dyne Therapeutics, Inc. has been rated by research analysts at Morgan Stanley, Piper Sandler, Jefferies, Oppenheimer, Chardan Capital, H.C. Wainwright in the past 90 days.